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Introduction
A major challenge in the development of new pharmaceutical products is drug bioavailability, [1] [2] [3] [4] particularly given the increasing trend towards more hydrophobic active pharmaceutical ingredients (APIs). [5] [6] [7] One of the main issues affecting bioavailability is the solubility of the drug in water. 8 Cocrystallization, salt formation and the use of metastable polymorphs have been among the methods employed to help drug solubility and dissolution rate. 9 There is also increasing interest in amorphous drugs and a number of formulations containing amorphous APIs are now commercially available (e.g. zafirlukast, cefuroxime axetil, quinapril hydrochloride and nelfinavir mesylate). 10 As the amorphous state is less thermodynamically stable than the crystal, amorphous materials are generally (initially) more water soluble and hence more bioavailable. 11 However, both preparing and stabilizing amorphous materials is often challenging. Amorphous materials can be chemically less stable than crystalline compounds, more hygroscopic and can display a tendency to convert to crystalline form over time. 12 One way to help prevent crystallization, and both chemically and physically stabilize molecules in an amorphous form is the addition of a second component. This is commonly done with a polymer 13 with the associated disadvantage that relatively large molecular weight proportions are required vs. the drug quantity, often referred to as drug load.
An alternative to the use of polymers is to use small molecules as stabilizers, creating a coamorphous mixture. 2, 10, 14 Coamorphous materials are similar in concept to cocrystals, [15] [16] [17] [18] [19] in that the second component is often complementary to the drug substance, but unlike cocrystals, 3 the goal is to disrupt favorable interactions which promote crystal formation while promoting drug-coamorphous-former interactions to stabilize the API on a local level. In addition to coamorphous phases and polymer dispersions, other approaches have been used to stabilize amorphous drugs including stabilization by inorganic and mesoporous materials such as silica. 20 One of the most common polymers used in amorphous dispersions is polyvinylpyrrolidone (PVP or povidone, 1). 21 PVP is a very common formulation agent, stabilizer and viscosity enhancer with applications in hydrate inhibition chemistry, haircare, cosmetics, shampoos and drilling fluids as well as in the pharmaceutical sector. The highly polar lactam carbonyl group imparts excellent electron donor and hydrogen bond acceptor ability without significant hydrogen bond acidity. PVP is commonly used in drug formulation, [22] [23] [24] often as a binding and bulking agent when making tablets or for potentially creating delayed release formulation based on its thermal behavior. PVP is also highly effective as a stabilizing agent for amorphous forms of drugs in polymer dispersions. [25] [26] [27] Common techniques for producing API-polymer dispersions include microprecipitation, ball milling, spray drying and hot-melt extrusion, although the inherent instability of polymer-amorphous API dispersions means that there are fewer commercial products of this type than might be expected. 28 Though PVP is effective at stabilizing the amorphous form of a range of drugs, a high loading is often required to ensure long-term stability typically 50 -80 % by mass. 29 Amorphous nifedipine requires a 1:4 ratio by mass with PVP, for example. 26 While a high loading is not necessarily a problem for drugs with a small therapeutic index, drugs which require a larger dosage would either need tablets too large to easily swallow or multiple 'units' per dose, neither of which are preferable for the patient, with strong evidence showing the negative impact this has on the treatment of disease. 30 Moreover, ingestion of large amounts of PVP have been suggested to cause unpleasant side 4 effects such as diarrhoea. 31 The other main disadvantage of PVP is that it is hygroscopic. 32 This property can reduce the shelf life of the product, either by water promoted degradation of the drug, or because water can cause a plasticizing effect in pills, aiding molecular mobility and crystallization. 33 As a result a less hygroscopic, lower loading alternative to PVP might be of potential utility. Small molecules such as pyrogallol, 14 amino acids 20, [34] [35] and drug mixtures 36 have all previously been shown to be effective in stabilizing the amorphous form of pharmaceuticals by forming a coamorphous phase rather than a polymer dispersion. In the present work we report studies aimed at the formation of stable coamorphous API phases with low molecular weight dilactams 3 -8 which are analogs of PVP (1) As expected, a control sample of ROY without any coformer readily crystallizes. It is interesting to note that under the conditions used, ROY crystallizes into three distinctive regions of different color suggesting that at least three different forms can be made from cooling the melt 6 in this way as previously reported by Chen et al. 43 who observed that cooling ROY from the melt results in the concomitant formation of four polymorphs. The Y04 form is initially produced, and cross-nucleates allowing different, faster growing forms to crystallize, resulting in a mixture of polymorphs from the same cooling crystallization. suggesting that these compounds influence polymorphic outcome but are ultimately ineffective at coamorphous phase formation. The polymorphism of ROY is well documented 37 and the crystal forms resulting from the present experiments were not further characterized. All of the samples were stored for a further two months at room temperature and periodically re-examined.
Results and Discussion
ROY Screening
No further changes were observed implying that all crystallization was complete within the first 8 24 hours and that the coamorphous phases formed by the two polymers and small molecule coformer bisVCap are stable for prolonged periods.
Screening of bisVCap and bisVP with a range of drugs
As bisVCap shows potential as an amorphous phase stabilizer for ROY, this compound along with the closely related bisVP was screened as a stabilizer for coamorphous phase formation with a range of other APIs. Twelve drugs were chosen for screening based on availability, thermal stability and a range of chemical functionality, Scheme 2..
Scheme 2.
APIs and ROY used in coamorphous screening.
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The drug compounds shown in Scheme 2 were ground together in a 1:1 mol ratio using a mortar and pestle with bisVCap and with bisVP before being heated on glass slides using a hot stage microscope until all material had melted. Control samples without lactam coformers were also prepared for comparison. The slides were then allowed to cool to room temperature. The samples were examined using optical microscopy after storing them overnight and again two weeks after melting to assess their crystallinity. Optical micrographs are shown in Figure 2 . Valsartan, even on its own, remains amorphous, consistent with the fact that the drug is marketed in a stable amorphous form, 44 although crystalline forms are also known but can be hard to prepare. 45 The samples prepared using bisVP (which is itself an oil) all become viscous fluids, and hence are The same heat-cool-heat cycles used in the DSC experiments were reproduced using a hot stage attached to a polarized light microscope for 1:1 mixtures of carisoprodol, carbamazepine, isoniazid and ROY with bisVCap. The results of the microscope experiments can be seen in the supporting information (Fig. S2 -S5 ) and confirm coamorphous phase formation. One major problem with PVP as an amorphous stabilizer is that often a large amount is required for stabilization of the amorphous phase. This often leads to very large tablets or dosage forms which consist of multiple tablets. Thus further hot stage microscope and DSC experiments of bisVCap mixtures with carisoprodol, carbamazepine, isoniazid and ROY were performed with increasing drug:bisVCap ratios to determine the minimum ratio of coformer required to maintain the API in an amorphous state.
For the microscope experiments the target drug or drug-like compounds and bisVCap were ground in the desired ratio, heated until all of the sample had melted then cooled back to room temperature and analyzed by polarized light microscopy. Carbamazepine, carisoprodol, isoniazid and ROY all showed no visible crystallization at a 2:1 drug:bisVCap molar ratio.
Carisoprodol also did not show any visible crystallization at a 3:1 carisoprodol:bisVCap ratio. At Neither isoniazid:bisVCap 2:1 or isoniazid:bisVCap 1:1 proved to be amorphous by XRPD.
Comparison to powder patterns calculated from the literature crystal structures of isoniazid 47 and bisVCap 48 shows the material to be a mixture of the two known materials (supporting information, Figure S6 ). While the observation of crystalline material by XRPD is not consistent with the optical microscopy and DSC data, and it is likely that the crystallization of this mixture Similarly, both carbamazepine and isoniazid show a large degree of broadening of the carbonyl peaks in the spectra of the cooled samples after melting while there is no change in the coground sample. The spectra of cooled melts of samples of carbamazepine:bisVCap and isoniazid:bisVCap showed no change between the 1:1 and 2:1 ratios. On the other hand, ROY exhibits no change in peaks in the IR spectra in the ground or melted samples at either a 1:1 or 2:1 ROY:bisVCap ratio. Even when melted and cooled, the spectrum for ROY/bisVCap is a mixture of the bisVCap and ROY spectra, with no shifts in the peaks of interest. This suggests that unlike carbamazepine, carisoprodol and isoniazid, which see significant changes to the local environment, the stabilization of the amorphous form in ROY/bisVCap does not arise from local intermolecular interactions.
A significant issue with PVP as an amorphous stabilizer is its hygroscopicity. 32 Dynamic vapor sorption (DVS) has been used to compare the water uptake of bisVCap with PVP. 52 The 
Conclusion
In conclusion, bisVCap appears to be a suitable small-molecule coamorphous phase former for a range of drugs and drug-like compounds, in some cases even at high drug-to-coformer ratio.
Carisoprodol in particular showed promise, with a low loading of bisVCap and a long shelf life. BisVCap is also much less hygroscopic than PVP. The concept of adapting small-molecule analogs of known polymeric dispersions as coformers for coamorphous phases is a potentially interesting avenue for future work.
Experimental
Differential scanning calorimetry
Differential scanning calorimetry scans were recorded in standard mode on a TA Q2000 using standard aluminum pans containing 3 -12 mg of sample. The heat/cool/heat cycles began with a heating cycle at a rate of 10 °C min -1 , then cooling cycle at 10 °C min -1 and finally a second heating cycle at 10 °C min -1 .
Dynamic vapor sorption
DVS was performed using an SMS DVS-1 with a 10 %RH step between humidity values with equilibrium achieved at 0.01% weight change before moving to the next step. Methods began at the humidity of the room at ambient which was measured by a Rotronic A/H hygrometer. The humidity was then increased to 90%RH before cycling to 0%RH, to 90%RH, to 0%RH. Samples weighing between 5-20mg were used.
Hot stage microscopy
A Linkam LTS420 heating stage attached to an Olympus XC50 microscope was used to heat the samples. Samples were placed on a glass microscope slide with a thin glass cover slide. For the amorphous material screening compounds were ground together in various drug to coformer ratio using 0. 
Infrared spectroscopy
Experiments were performed on a Perkin Elmer FTIR spectrum 100 with an attenuated total reflectance (ATR) attachment. Data were recorded at a resolution of 2 cm -1 for 16 scans over the range 4000 -600 cm -1 . Samples were run by placing on the ATR crystal and applying pressure using the side arm. Spectral analysis was performed using SpekWin32. Ground samples were prepared by grinding together in the desired ratio of the two components using a mortar and pestle for one minute. Melted samples were prepared by grinding together in the desired ratio of the two components using a mortar and pestle for one minute before placing the ground material into 5 mL glass vial with a plastic screw lid. After the lid was secured the sample was heated above the melting point of the highest melting component until everything had melted using a stirrer hotplate and appropriate heating block.
Crystallographic analysis
X-ray powder diffraction patterns were recorded on a PANalytical Empyrean diffractometer and diffracted beam anti-scatter slit of 7.5 mm.
Materials and Methods
Compounds 3 -7 were prepared according to previously published procedures. 52 The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.
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